biopharma-dealmaker
(2)
Han Lee
Han Lee, Ph.D., is co-CEO of Vibrant Therapeutics, a clinical-stage biotech building logic-gated, conditionally activated antibody prodrugs designed to switch on only inside diseased tissue. A Yale-trained geneticist with an MBA who can read a sequencing run and a term sheet with equal fluency, Lee spent 15 years as the finance and dealmaking engine behind cell-therapy companies - Arcellx, Neogene, and ImmPACT Bio - steering more than 75 transactions worth billions, including two startup exits to AstraZeneca and Lyell Immunopharma. In January 2026 he joined founder Larry Wang to scale Vibrant globally and push its lead masked T-cell engager, VIB305, into the clinic.
Josh Carle
Josh Carle is the Chief Business Officer of Hinge Bio, a Burlingame, California biotech building multivalent, multispecific antibody therapies on its GEM-DIMER platform. A dealmaker by trade, he has led or advised more than fifty strategic transactions worth over $2 billion in disclosed deal value, moving from Pfizer Oncology and Daiichi Sankyo to immuno-oncology startup Triumvira before joining Hinge Bio in January 2023 to steer its lead lupus program toward the clinic.